FDA Approves Trelegy Ellipta for COPD

1031 Views

eMediNexus 23 September 2017

The US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate (10 µg)/umeclidinium (62.5 µg)/vilanterol (25 µg) (Trelegy Ellipta, GlaxoSmithKline) for patients with chronic obstructive pulmonary disease (COPD). It is not indicated for acute bronchospasm or asthma.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.